摘要
目的 比较寡转移前列腺癌内分泌治疗联合或不联合前列腺原发灶放疗的疗效。方法 回顾性分析2014年1月至2017年6月就诊的寡转移前列腺癌患者69例,均经活检病理确诊,其中内分泌治疗联合前列腺原发灶放疗24例,单纯内分泌治疗45例。比较两组患者的临床特征及3、5年生存率,观察急性放疗不良反应。计量资料行t检验,计数资料行χ2检验,用K-M法计算生存率并Log-rank检验。结果 内分泌治疗联合原发灶放疗组的预后明显优于单纯内分泌治疗组,内分泌治疗联合原发灶放疗组与单纯内分泌治疗组的中位生存时间分别为61和42个月,内分泌治疗联合原发灶放疗组与单纯内分泌治疗组3、5年的生存率分别为82.3%和53.4%、49.6%和22.7%(P=0.010,χ2=6.668)。放疗组1~2级急性直肠反应33.3%,1级急性尿道反应20.8%,1级白细胞减少16.7%。1~2级慢性直肠反应12.5%,1级慢性尿道反应12.5%。结论 寡转移前列腺癌内分泌治疗联合原发灶放疗可提高患者生存率,且放疗不良反应轻微。
Objective To compare the efficacy of endocrine therapy combined with or without primary radiotherapy for oligometastatic prostate cancer.Methods A retrospective analysis was performed to investigate a total of 69 patients with oligometastatic prostate cancer who received endocrine therapy combined with or without primary radiotherapy from January 2014 to June 2017.All patients were pathologically diagnosed with prostate cancer by biopsy.24 patients were treated with endocrine therapy combined with primary radiotherapy for prostate,and 45 patients were treated with endocrine therapy alone.The clinical characteristics,3-year and 5-year survival rates were compared between the two groups.Observe the adverse reactions of acute radiotherapy.t test of measurement data,χ2 test of counting data.The Kaplan-Meier method was used for survival analysis and Log-rank test.Results The prognosis of the endocrine therapy combined with primary radiotherapy group was significantly better than that of the endocrine therapy alone group.The median survival time of the endocrine therapy combined with primary radiotherapy group and endocrine therapy alone group was 61 months and 42 months,the 3-year,5-year survival rates were 82.3% and 53.4%,49.6% and 22.7%,P=0.010,χ2=6.668.In the radiotherapy group,grade 1-2 acute rectal reaction was 33.3%,grade 1 acute urethral reaction was 20.8%,and grade 1 leukopenia was 16.7%.Grade 1-2 chronic rectal reaction was 12.5%,grade 1 chronic urethral reaction was 12.5%.Conclusion Endocrine therapy combined with primary radiotherapy for oligometastatic prostate cancer may improve survival,and the adverse effects of radiotherapy are mild.
作者
林建贵
陈丽民
卓延红
万金平
陈金飚
LIN Jiangui;CHEN Limin;ZHUO Yanhong;WAN Jinping;CHEN Jinbiao(Department of Urology,Zhangzhou Affiliated Hospital of Fujian Medical University,Zhangzhou 363000,China;Department of Radiotherapy,Zhangzhou Affiliated Hospital of Fujian Medical University,Zhangzhou 363000,China)
出处
《中国医药指南》
2022年第36期82-84,共3页
Guide of China Medicine
关键词
寡转移前列腺癌
内分泌治疗
雄激素剥夺治疗
放疗
Oligometastatic prostate cancer
Endocrine therapy
Androgen deprivation therpy
Radiotherapy
